Primary hepatocellular carcinoma (HCC) accounts for more than 5% of all cancers in the world, and causes between 250,000 and one million deaths globally each year. The incidence of portal vein thrombosis in HCC patients is around 8%. These patients are regarded as unsuitable for chemoembolization, especially if there is portal vein occlusion. The authors describe a patient with HCC and partial portal vein thrombosis who successfully underwent transarterial chemoembolization.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.